Effect of Ulinastatin Combined with Somatostatin on Intestinal Mucosal Barrier Function and Inflammatory Factor Levels in the Treatment of Patients with Acute Pancreatitis
ZHANG Yongshan
HU Dingmei
RUAN Lihua
Abstract：Objective:To investigate the effect of the combination of ulinastatin and somatostatin in patients with acute pancreatitis(AP).Method:A total of 100 AP patients admitted to Bijie Hospital of Zhejiang Provincial People's Hospital from January 2023 to January 2024 were selected as the study objects and divided into control group and observation group by random number table method,with 50 cases in each group.The control group was treated with somatostatin for injection,and the observation group was treated with ulinastatin for injection on the basis of the control group.The clinical efficacy,intestinal barrier function indexes,inflammatory factors and adverse reactions were compared between the two groups.Result:The total effective rate of observation group was higher than that of control group,and the difference was statistically significant(P<0.05).After treatment,the levels of D-lactic acid(D-Lac),endotoxin(ET),diamine oxidase(DAO),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and hypersensitive C-reactive protein(hs-CRP)in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Ulinastatin combined with somatostatin can enhance the therapeutic effect,improve the intestinal mucosal barrier function and reduce the inflammatory response in AP patients,and the drug has high safety.
Keywords：Acute pancreatitisUlinastatinSomatostatinIntestinal mucosal barrier functionLevel of inflammatory factors
Publication Date：2025-05-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 34-37 )